| Literature DB >> 33142771 |
Saheed E Elugoke1,2, Abolanle S Adekunle1,2,3, Omolola E Fayemi1,2, Bhekie B Mamba4, El-Sayed M Sherif5,6, Eno E Ebenso1,7.
Abstract
Imbalance in the levels ofEntities:
Keywords: carbon quantum dots; electrochemical sensors; graphene quantum dots; neurotransmitters
Mesh:
Substances:
Year: 2020 PMID: 33142771 PMCID: PMC7693402 DOI: 10.3390/bios10110162
Source DB: PubMed Journal: Biosensors (Basel) ISSN: 2079-6374
Figure 1Monoamine neurotransmitters.
Figure 2(a) The architecture of semiconducting inorganic quantum dots (adapted from [41] with modification); (b) Graphene quantum dots; (c) Carbon quantum dots (reproduced with permission [69]-published by the Royal Society of Chemistry); (d) Heteroatom (blue atom) doped graphene quantum dots.
Figure 3TEM micrograph of (A) GQDs from graphite (Adapted from [79]) (B) CQDs from glucose (Adapted from [80]) (C) GQDs from CA (Adapted from [81]) (D) CQDs from glucose (adapted from [82]) (E) NCQDs from DEA (adapted from [83]) (F) NGQDs from CA and Urea (adapted from [84]).
Similarities and differences between GQDs and CQDs.
| GQDs and CQDs Similarities | GQDs and CQDs Differences |
|---|---|
|
They both possess sp2 hybridized carbon atoms They both possess quantum confinement with optical properties varying with the size They are both biocompatible with good electrocatalytic activity towards biomolecules Their electrocatalytic activity and chemical stability can be improved by doping with heteroatoms They have very small particle sizes ranging from 2–100 nm in diameter |
CQDs are mostly amorphous while GQDs are largely crystalline in nature. CQDs are largely carbon nanomaterials with graphitic core while GQDs are made up of less than ten layers of graphene. CQDs are often made from carbohydrate, citric acid and biomass such as leaves, grasses or hair fibre while GQDs are mostly made from graphene. |
Figure 4Cyclic voltammogram showing: (A) Potential against time (Reprinted with permission from [89]) (B) Current against potential. (Adapted from bioanalytical systems incorporated).
Figure 5Differential pulse voltammetry showing (A) Potential against time; and (B) Current against potential (Adapted from [104] copyright Elsevier, 2017).
Figure 6Square wave voltammetry showing (A) potential against time and (B) current against potential (Adapted from [104] copyright Elsevier, 2017).
Figure 7Linear sweep voltammetry showing (A) potential scan with time and (B) the voltammogram (Adapted from [109]).
Figure 8Chronoamperograms of different concentrations of an analyte (Adapted from [111]).
Figure 9Preparation of the His-GQDs-GMA nanocomposite (Reproduced from [97], copyright Elsevier, 2017).
Figure 10Preparation of Au-GQDS-Nafion-modified electrode for DA detection (Reprinted from [98], copyright Elsevier, 2019).
Figure 11Preparation of GQDs from pyrolysis of citric acid (reprinted from [114], Copyright Wiley-vch, 2018).
Scheme 1A general proposed mechanism for catecholamine neurotransmitters oxidation and reduction.
Scheme 2Proposed mechanism for serotonin redox reactions.
Figure 12GQDs production and electrochemical detection of DA using GQDs@MWCNTs composite (adapted from [113], 2020).
Figure 13Electrochemical detection of DA with composite (Reproduced from [80], copyright RSC, 2013).
Figure 14Mechanism for the selective dopamine determination in the presence of AA and UA at physiological pH (taking modified GCE as standard).
Table of the figures of merit for dopamine (DA) determination using graphene and carbon quantum dots (GQDs & CQDs).
| Electrode Support | Electrode | Technique | LOD (nM) | LDR (µM) | Peak Difference (mV) | pH | Supporting Electrolyte | Validating Sample | Ref. |
|---|---|---|---|---|---|---|---|---|---|
| AA-DA UA-DA AA-UA | |||||||||
| GQDs | GQDs/GCE | DPV | 50 | 0.4–100 | 148 - - | 7.0 | 0.1 M PBS | DA injection | [ |
| Au-GQDs/Nafion/GCE | DPV | 840 | 2–50 | - - - | 7.4 | 0.1 M PBS | Human urine (HU) | [ | |
| CS/N-GQDs/SPCE | DPV | 145 | 1–200 | 171 46 - | 7.0 | 0.1 M PBS | HU | [ | |
| GQDs-Nafion/GCE | DPV | 0.45 | 0.005–100 | - - - | 7.0 | 0.1 M PBS | DA injection | [ | |
| GQDs-eth/GCE | DPV | 115 | 1–150 | 288 194 - | 7.0 | 0.1 M PBS | DA injection | [ | |
| SnO2/PANI/N-GQDs/GCE | DPV | 220 | 0.5–200 | 288 199 - | 7.0 | - | - | [ | |
| GQDs-TMSPED-AuNCs/GCE | AP | 5 | 0.005–2.1 | - b 412 - | 7.0 | 0.1 M PBS | DA injection & HU | [ | |
| H-GQDs-GMA | DPV | 0.29 | 0.001–80 | - - - | 7.0 | 0.01 M PBS | Rat brain | [ | |
| GQDs/MWCNTs/GCE | DPV | 95 | 0.25–250 | - - - | 7.0 | 0.1 M PBS | Human serum (HS) | [ | |
| GQDs/SPE | DPV | 500 | 1–900 | a 435 - - | 7.0 | 0.1 M PBS | DA ampoule & Urine | [ | |
| CQDs | CD-CQDs/GCE | DPV | 140 | 4–220 | - b 150 c 420 | 7.0 | 0.1 M PBS | Urine | [ |
| GCE/CQDs | DPV | 4.6 | 0.05–2 | - - - | 7.0 | 0.1M PBS | Urine | [ | |
| GCE-CQDs | LSV | 2700 | 0.19–11.81 | - - - | 7.0 | 0.05 M PBS | - | [ | |
| CQDs-CS/GCE | DPV | 11.2 | 0.1–30 | - - - | 7.0 | 0.5 mM PBS | DA injection | [ | |
| IL-graphene/CQDs/GCE | DPV | 30 | 0.1–600 | - - - | 6.5 | PBS | Bovine serum | [ | |
| NCQDs-nafion/GCE | DPV | 1.0 | 0.0–1000 | - 760 340 | 7.4 | 0.1 M PBS | - | [ | |
| NCQDs/GCE | DPV | 1.2 | 0.05–800 | 580 - - | 6.5 | PBS | HS and HU | [ | |
| CQDs/GCE | DPV | 26 | 0.15–150 | - - - | 6.0 | 0.1 M PBS | Human plasma | [ | |
| AuNP/CQDs-CS/GCE | DPV | 1.0 | 0.1–30 | - - - | 7.0 | 0.5 mM PBS | DA injection | [ | |
| Cu2O-CQDs/Nafion/GCE | DPV | 1.1 | 0.05–45 | - - - | 7.0 | 0.1 M PBS | HS | [ | |
| CQDs/SPCE | CV | 99 | 1–7 | - - - | 7.4 | 0.1 M PBS | HU | [ |
a represents DA-tyr peak separation, b represents DA-EP peak separation and, c represents UA-trp peak separation.
Figure 15Electrochemical detection of EP using GQDs/Chitosan composite (Reproduced from [86]).
Table of the figures of merit of other monoamine NTs (EP, SE and NE) determination using graphene and carbon quantum dots (GQDs & CQDs).
| Monoamine NTs | Electrode Support | Electrode | Technique | LOD (nM) | LDR (µM) | Interfering Species | pH | Supporting Electrolyte | Validating Sample | Ref. |
|---|---|---|---|---|---|---|---|---|---|---|
| Epinephrine | GQDs | GQDs/CS/CPE | CAP | 0.3 | 0.36–380 | Glc, suc, fru, cys, asp, ala, glu, his, arg, gly & trp | 7.0 | 0.1 M PBS | Blood serum & EP injection | [ |
| GCE/GQDs/Lac | CV | 83.0 | 1–120 | AA, UA, trp, cys & glu | 5.2 | 0.1 M PCB | EP injection | [ | ||
| CQDs | MIP/g-C3N4/NCQDs/GCE | DPV | 0.0003 | 0.001–1 | DA, AA, UA, tyr & trp | 7.5 | 0.1 M PBS | Human urine | [ | |
| CQDs/CPE | DPV | 6.0 | 0.02–20 | SE & AA | 7.4 | 0.1 M PBS | EP injection | [ | ||
| Serotonin | GQDs | MIP/h-BN/GQDs/GCE | DPV | 0.0002 | 0.001–10 | DA, NE & tyr | 7.0 | 0.1 M PBS | Human urine | [ |
| CQDs | CQDs/CPE | DPV | 4.0 | 0.01–8 | AA & EP | 7.4 | 0.1 M PBS | - | [ | |
| Norepinephrine | GQDs | GQDs-AuNPs/GCE | SWSV | 150 | 0.5–7.5 | AA & UA | 7.0 | 0.1 M PBS | NE injection & rat brain tissue | [ |
| GQDs/IL/CPE | DPV | 60 | 0.2–400 | ACh | 7.0 | 0.1 M PBS | NE injection & human urine | [ |